1. Home
  2. MIRM vs NATL Comparison

MIRM vs NATL Comparison

Compare MIRM & NATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • NATL
  • Stock Information
  • Founded
  • MIRM 2018
  • NATL 2023
  • Country
  • MIRM United States
  • NATL United States
  • Employees
  • MIRM N/A
  • NATL N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • NATL
  • Sector
  • MIRM Health Care
  • NATL
  • Exchange
  • MIRM Nasdaq
  • NATL Nasdaq
  • Market Cap
  • MIRM 3.3B
  • NATL 2.9B
  • IPO Year
  • MIRM 2019
  • NATL N/A
  • Fundamental
  • Price
  • MIRM $73.14
  • NATL $39.30
  • Analyst Decision
  • MIRM Strong Buy
  • NATL Buy
  • Analyst Count
  • MIRM 10
  • NATL 4
  • Target Price
  • MIRM $74.20
  • NATL $42.75
  • AVG Volume (30 Days)
  • MIRM 679.0K
  • NATL 651.4K
  • Earning Date
  • MIRM 11-11-2025
  • NATL 11-11-2025
  • Dividend Yield
  • MIRM N/A
  • NATL N/A
  • EPS Growth
  • MIRM N/A
  • NATL N/A
  • EPS
  • MIRM N/A
  • NATL 1.71
  • Revenue
  • MIRM $429,161,000.00
  • NATL $4,271,000,000.00
  • Revenue This Year
  • MIRM $53.08
  • NATL $2.73
  • Revenue Next Year
  • MIRM $20.45
  • NATL $4.51
  • P/E Ratio
  • MIRM N/A
  • NATL $23.04
  • Revenue Growth
  • MIRM 62.33
  • NATL N/A
  • 52 Week Low
  • MIRM $36.86
  • NATL $22.30
  • 52 Week High
  • MIRM $78.10
  • NATL $40.78
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 58.57
  • NATL 58.96
  • Support Level
  • MIRM $73.35
  • NATL $38.43
  • Resistance Level
  • MIRM $74.99
  • NATL $40.47
  • Average True Range (ATR)
  • MIRM 2.37
  • NATL 1.01
  • MACD
  • MIRM -0.94
  • NATL -0.36
  • Stochastic Oscillator
  • MIRM 20.40
  • NATL 52.26

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About NATL NCR Atleos Corporation

NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.

Share on Social Networks: